Who founded Adcytherix?

Adcytherix was founded by Jack Elands, Xavier Preville in 2022.

Who are Adcytherix's investors?

Adcytherix's investors include aMoon, RA Capital, Bpifrance, Andera Partners, Angelini Ventures, Kurma Partners, Pontifax Venture Capital, Pureos Bioventures.

Adcytherix

Founded 2022 · 3 employees on LinkedIn · 8 known investors

Find your way into Adcytherix

Paths you didn't know you had: your email and LinkedIn already hold routes to the Adcytherix team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology. Its lead candidate, ADCX-020, is being evaluated in a Phase 1 study in patients with advanced solid tumors.

Biotech Healthtech Medical Devices

Founders & leadership

Adcytherix was founded in 2022 by Jack Elands and Xavier Preville.

Jack ElandsFounder & CEO

Xavier Preville Co-founder, VP & Head of Research & Preclinical DevelopmentXavier Preville is co-founder, VP, and Head of Research & Preclinical Development at Adcytherix, a clinical-stage biopharmaceutical company developing antibody-drug conjugates for precision oncology. He has over 20 years of biotech experience as a preclinical group and department head specializing in onco-immunology, with expertise in translational medicine, biomarker assay development and validation in GLP settings, and managing external collaborations with CMOs, CROs, and academic teams.

Jan H.M. Schellens Chief Medical OfficerJan H.M. Schellens is Chief Medical Officer at Adcytherix and holds expertise in medical oncology, clinical pharmacology, and translational research. He served as chairperson of the EMA's Scientific Advisory Group for Oncology from 2010 to 2016 and held leadership roles in multiple European clinical pharmacology and oncology research organizations.

Thierry Menguy VP & Head of CMC OperationsThierry Menguy holds a PhD and brings 25 years of biotechnology research experience, with expertise in biologics drug development from discovery through clinical Phase 3, including CMC activities and regulatory submissions for monoclonal antibodies, recombinant proteins, and viral vectors. He serves as VP and Head of CMC Operations at Adcytherix, a clinical-stage biopharmaceutical company developing antibody-drug conjugates for precision oncology.

Jaime Arango Chief Financial OfficerJaime Arango is Chief Financial Officer of Adcytherix, a clinical-stage biopharmaceutical company developing antibody-drug conjugates for oncology. He brings over 20 years of biotech and life sciences finance experience, including leadership through IPOs, capital raises, FP&A systems design, ERP implementations, and management of global finance teams across multiple countries.

Paul JacksonChief Operating Officer

Magali Gibou Chief Regulatory & Quality OfficerMagali Gibou has 24 years of regulatory affairs experience across oncology, CNS, hemophilia, and autoimmune diseases, with expertise in global regulatory strategies for small molecules, biologics, cell and gene therapies, and companion diagnostics across US and international markets. She previously held a regulatory role in a matrix organization at a large pharmaceutical company.

Inka Pawlitzky VP & Head of Clinical DevelopmentInka Pawlitzky is VP and Head of Clinical Development at Adcytherix, a clinical-stage biopharmaceutical company developing antibody-drug conjugates for oncology. She has prior experience in clinical development strategy, regulatory affairs, and medical writing across oncology, immunology, and diagnostics.

Julia Gavrilyuk VP & Head of ADC Technology DevelopmentShe has extensive experience in antibody-drug conjugate development, having advanced eight ADC programs through clinical trials from Phase I to Phase II/III, and previously led discovery-to-development efforts in oncology drug programs while building multidisciplinary research teams.

Investors · 8

aMoon✓ confirmed by AdcytherixRa'anana

How we know: the company's own site · aMoon's portfolio page · Not right? Tell us

RA Capital✓ confirmed by AdcytherixBoston

How we know: RA Capital's portfolio page · the company's own site · Not right? Tell us

Bpifrance✓ confirmed by AdcytherixParis, Ile-De-France · $270K

How we know: the company's own site · Not right? Tell us

Andera Partnerslisted by Andera PartnersParis

How we know: a partner's Signal profile · Not right? Tell us

Angelini Ventureslisted by Angelini VenturesRome

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Kurma Partnerslisted by Kurma PartnersParis · $162K – $10.8M

How we know: Kurma Partners's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Pontifax Venture Capitallisted by Pontifax Venture CapitalHerzeliya

How we know: Pontifax Venture Capital's portfolio page · a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Pureos Bioventureslisted by Pureos BioventuresPfäffikon

How we know: Pureos Bioventures's portfolio page · Not right? Tell us

Funding

SEC filings, press & company announcements

Undisclosed amountSeries AOct 2025 · 2 sources
Source ↗
Undisclosed amountseed fundingJun 2024 · 2 sources
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloadsglobenewswire.com · Oct 2025

With its notable €105 million raise, French BioTech startup Adcytherix looks to tackle cancer with novel ADC | EU-Startupseu-startups.com · Oct 2025

Adcytherix Raises €30M in Seed Fundingfinsmes.com · Jun 2024

Frequently asked questions

What does Adcytherix do?: Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology. Its lead candidate, ADCX-020, is being evaluated in a Phase 1 study in patients with advanced solid tumors.
Who founded Adcytherix?: Adcytherix was founded by Jack Elands, Xavier Preville in 2022.
Who are Adcytherix's investors?: Adcytherix's investors include aMoon, RA Capital, Bpifrance, Andera Partners, Angelini Ventures, Kurma Partners, Pontifax Venture Capital, Pureos Bioventures.